| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 29, 2014I dati dello studio EVOLVE presentati nell'ambito dell’EuroPCR 2014 hanno dimostrato un eccellente profilo di sicurezza
Boston Scientific Corporation (NYSE: BSX) ha riportato dati positivi di follow-up a tre anni dello studio clinico EVOLVE, che confronta la sicurezza e la performance di SYNERGY™, stent...
-
May 27, 2014Solo l'1,1% dei pazienti ha manifestato rigurgito aortico paravalvolare moderato; non si sono verificati casi severi
Con un'ulteriore conferma della sua tecnologia avanzata per l'impianto transcatetere della valvola aortica (TAVI), il dispositivo Lotus?, di Boston Scientific Corporation (NYSE: BSX), continua a...
-
May 22, 2014Only 1.1 Percent of Patients Experienced Moderate Paravalvular Aortic Regurgitation; No Severe Cases Occurred
Further validating its advanced transcatheter aortic valve implantation (TAVI) technology, the Boston Scientific Corporation (NYSE: BSX) Lotus™ Valve System continued to demonstrate impressive...
-
May 16, 2014Patients In Germany Receive New Transcatheter Aortic Valve Implantation Devices Specially Designed For Total Control And Accurate Deployment
Marking a major step forward in the evolution of Transcatheter Aortic Valve Implantation (TAVI) technology, the first two commercial implants of the Boston Scientific (NYSE: BSX) Lotus™ Valve...
-
May 16, 2014
The U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee voted favorably by a majority, Yes: 13, No: 1, that the benefits of the...